Key points are not available for this paper at this time.
Abstract Chronic lymphocytic leukemia (CLL) is a mature‐type B cell malignancy correlated with significant changes and defects in both the innate and adaptive arms of the immune system, together with a high dependency on the tumor microenvironment. Overall, the tumor microenvironment (TME) in CLL provides a supportive niche for leukemic cells to grow and survive, and interactions between CLL cells and the TME can contribute to disease progression and treatment resistance. Therefore, the increasing knowledge of the complicated interaction between immune cells and tumor cells, which is responsible for immune evasion and cancer progression, has provided an opportunity for the development of new therapeutic approaches. In this review, we outline tumor microenvironment‐driven contributions to the licensing of immune escape mechanisms in CLL patients.
Taghiloo et al. (Thu,) studied this question.